|
|
|
| Predictive Value of Combined Detection of Follicle-Stimulating Hormone, Estradiol and Progesterone in Female Infertility |
| WU Liping, CHANG Xiaoling, WANG Hongmei |
| Department of Laboratory Medicine, Pingdingshan Institute of Reproductive Medicine, Pingdingshan Henan 467000 |
|
|
|
|
Abstract 【Objective】 To investigate the predictive value of combined detection of follicle-stimulating hormone (FSH), estradiol (E2) and progesterone (P) in female infertility. 【Methods】 A total of 76 infertile patients admitted to our hospital from March 2022 to March 2025 were selected as the observation group, and 76 healthy women who underwent physical examination in our hospital during the same period were selected as the control group. Univariate and multivariate Logistic regression analyses were used to screen influencing factors of female infertility, and receiver operating characteristic (ROC) curve was used to analyze the predictive efficacy of FSH, E2, P alone and in combination for female infertility. 【Results】 The levels of FSH, prolactin, luteinizing hormone and testosterone in the observation group were significantly higher than those in the control group, while the levels of E2 and P were significantly lower than those in the control group (P<0.05). There were no significant differences in age and body mass index (BMI) between the two groups (P>0.05). Multivariate Logistic regression analysis showed that elevated FSH, decreased E2 and decreased P were independent risk factors for female infertility (P<0.05). ROC curve analysis showed that the area under the curve (AUC) of combined detection of FSH, E2 and P in predicting female infertility was significantly larger than that of single detection of each index (P<0.05). Conclusion Abnormal levels of FSH, E2 and P are closely related to female infertility. 【Conclusion】 Combined detection of the three indicators can improve the predictive efficacy for female infertility and provide a reference for clinical prediction of female infertility.
|
|
Received: 27 August 2025
|
|
|
|
|
|
[1] CONCEPCION-ZAVALETA M J, CORONADO-ARROYO J C, QUIROZ-ALDAVE J E, et al. Endocrine factors associated with infertility in women: an updated review[J].Expert Rev Endocrinol Metab,2023, 18(5): 399-417.
[2] 孙雅宁,许宁,陈银银,等. 全球204个国家和地区1990—2019年不孕症疾病负担分析及预测[J].中华生殖与避孕杂志,2025,45(3):277-285.
[3] 王艳华,张金娜,汪俊红,等. 不孕症夫妇社会支持、心理弹性和人格特征的性别差异现状及对生活质量影响[J].中国计划生育学杂志,2024,32(10):2248-2254.
[4] 黄卓华,黄涛,雷嘉,等. 慢性子宫内膜炎患者血清性激素水平与不孕症的关系[J].中国性科学,2023,32(3):93-97.
[5] 孙晓华,宋雨霖,李红,等. 血清CCL18、sB7-H3水平对子宫内膜异位症的诊断价值[J].检验医学与临床,2024,21(20):2965-2969.
[6] LIANG Y H, HUANG J, ZHAO Q, et al. Global, regional, and national prevalence and trends of infertility among individuals of reproductive age (15-49 years) from 1990 to 2021, with projections to 2040[J].Hum Reprod,2025, 40(3): 529-544.
[7] LI J J, WEI J J, CHEN S Q, et al. Prevalence and risk factors for chronic endometritis in patients with adenomyosis and infertility: a retrospective cohort study[J].BMC Women's Health,2024, 24(1): 403.
[8] 许谦. 探讨血清性激素检测在女性不孕症辅助诊断中的应用价值[J].现代科学仪器,2024,41(3):99-101.
[9] 史丽娜,谢飞,田野,等. 联合抗缪勒管激素、硫酸脱氢表雄酮与性激素诊断多囊卵巢综合征的探讨[J].标记免疫分析与临床,2024,31(10):1770-1774.
[10] 张皙卉,卢静,和伟. 重组人生长激素辅助治疗对高龄不孕IVF-ET患者血清FSH、E2及LH水平的影响[J].分子诊断与治疗杂志,2024,16(8):1437-1440.
[11] 谢秋月,赵小凤,张湘琪,等. 促卵泡激素与孕卵指数在不同临床表型多囊卵巢综合征不孕患者中的差异及与促排卵结局的关系[J].中国妇幼健康研究,2025,36(2):53-62.
[12] 傅娣芳,李鑫伟,王亭亭,等. 戊酸雌二醇片结合来曲唑治疗排卵功能障碍致不孕症的疗效及对卵泡发育、排卵的影响[J].中国性科学,2023,32(2):105-109.
[13] 任学青,张凯,孙梦,等. 不孕女性血清抗苗勒管激素与雌二醇的相关性及预测辅助生殖妊娠价值[J].中国计划生育学杂志,2023,31(8):1888-1892.
[14] 王晨,满晓婷,王颖,等. 孕酮对鲫鱼胚胎发育和内分泌干扰效应[J].四川动物,2023,42(1):46-53.
[15] TOKGOZ V Y, TEKIN A B. Serum progesterone level above 0.85 ng/mL and progesterone/estradiol ratio may be useful predictors for replacing cleavage-stage with blastocyst-stage embryo transfer in fresh IVF/ICSI cycles without premature progesterone elevation[J].Arch Gynecol Obstet,2022, 305(4): 1011-1019. |
|
|
|
2026, Vol. 43 
